"Molekul\u00E1rn\u00ED patogeneze chronick\u00E9 lymfocyt\u00E1rn\u00ED leukemie"@cs . "16" . . "Plevov\u00E1, Karla" . "chronic lymphocytic leukemia; CLL; molecular pathogenesis"@en . "Mal\u010D\u00EDkov\u00E1, Jitka" . "Chronick\u00E1 lymfocit\u00E1rn\u00ED leukemie (CLL) je onemocn\u011Bn\u00EDm, u n\u011Bj\u017E v sou\u010Dasn\u00E9 dob\u011B doch\u00E1z\u00ED k \u010D\u00E1ste\u010Dn\u00E9mu posunu v terapeutick\u00FDch p\u0159\u00EDstupech a hodnocen\u00ED jejich \u00FAsp\u011B\u0161nosti (MRD negativita). P\u0159es ve\u0161ker\u00FD pokrok v t\u00E9to oblasti st\u00E1le chyb\u00ED hlub\u0161\u00ED pochopen\u00ED patogeneze CLL, co\u017E zt\u011B\u017Euje zlep\u0161en\u00ED l\u00E9\u010Dby a zvr\u00E1cen\u00ED \u0161patn\u00E9 progn\u00F3zy n\u011Bkter\u00FDch subtyp\u016F onemocn\u011Bn\u00ED. P\u0159i studiu CLL bylo zkoum\u00E1no n\u011Bkolik oblast\u00ED sm\u011B\u0159uj\u00EDc\u00EDch k vysv\u011Btlen\u00ED jej\u00ED patogeneze, kter\u00E9 by se zjednodu\u0161en\u011B daly shrnout do 3 skupin: signalizuje p\u0159es B-bun\u011B\u010Dn\u00FD receptor (BCR), naru\u0161en\u00ED apoptick\u00FDch drah a \u00FAloha mikroprost\u0159ed\u00ED. Biologie CLL je d\u00E1le komplikov\u00E1na \u010D\u00E1ste\u010Dn\u011B rozd\u00EDlnou genez\u00ED subtyp\u016F CLL s mutovan\u00FDm a nemutovan\u00FDm IgVh. R\u00E1di bychom zde stru\u010Dn\u011B shrnuli z\u00E1kladn\u00ED molekul\u00E1rn\u011B biologick\u00E9 dr\u00E1hy diskutovan\u00E9 v patogenezi CLL a jejich souvislosti s variabiln\u00ED progn\u00F3zou onemocn\u011Bn\u00ED a nov\u011B vyv\u00EDjen\u00FDmi l\u00E9\u010Divy."@cs . . "Molekul\u00E1rn\u00ED patogeneze chronick\u00E9 lymfocyt\u00E1rn\u00ED leukemie" . "P(NR9293), P(NR9301), P(NS10439), P(NS9858)" . . . . "Pavlov\u00E1, \u0160\u00E1rka" . . "6"^^ . . "Molekul\u00E1rn\u00ED patogeneze chronick\u00E9 lymfocyt\u00E1rn\u00ED leukemie"@cs . "RIV/00216224:14110/10:00056954!RIV12-MZ0-14110___" . "6"^^ . . "14110" . "272416" . "CZ - \u010Cesk\u00E1 republika" . . "RIV/00216224:14110/10:00056954" . . . "Mr\u00E1z, Marek" . . . . . . . "suppl. 1" . "Posp\u00ED\u0161ilov\u00E1, \u0160\u00E1rka" . "Molecular pathogenesis of chronic lymphocytic leukemia"@en . . . "In recent years, treatment approaches for chronic lymphocytic leukemia (CLL) partially improved including evaluation of their efficiency by MRD-negativity. However, the pathogenesis of CLL has not been clearly elucidated and this unables the development of more effective treatment strategies for unfavourable disease subtypes. The studies of CLL biology point to three major areas with pathogenetic relevance: BCR signaling, apoptotic defects and influence of the microenvironment. Moreover, the CLL biology is complicated by partially different history of the subtypes and their relation to variable prognosis and novel therapeutic compounds."@en . . "Mayer, Ji\u0159\u00ED" . . "1213-5763" . . "Molekul\u00E1rn\u00ED patogeneze chronick\u00E9 lymfocyt\u00E1rn\u00ED leukemie" . "Molecular pathogenesis of chronic lymphocytic leukemia"@en . . "Transfuze a hematologie dnes" . "[54A556F4CC2C]" . "5"^^ . "Chronick\u00E1 lymfocit\u00E1rn\u00ED leukemie (CLL) je onemocn\u011Bn\u00EDm, u n\u011Bj\u017E v sou\u010Dasn\u00E9 dob\u011B doch\u00E1z\u00ED k \u010D\u00E1ste\u010Dn\u00E9mu posunu v terapeutick\u00FDch p\u0159\u00EDstupech a hodnocen\u00ED jejich \u00FAsp\u011B\u0161nosti (MRD negativita). P\u0159es ve\u0161ker\u00FD pokrok v t\u00E9to oblasti st\u00E1le chyb\u00ED hlub\u0161\u00ED pochopen\u00ED patogeneze CLL, co\u017E zt\u011B\u017Euje zlep\u0161en\u00ED l\u00E9\u010Dby a zvr\u00E1cen\u00ED \u0161patn\u00E9 progn\u00F3zy n\u011Bkter\u00FDch subtyp\u016F onemocn\u011Bn\u00ED. P\u0159i studiu CLL bylo zkoum\u00E1no n\u011Bkolik oblast\u00ED sm\u011B\u0159uj\u00EDc\u00EDch k vysv\u011Btlen\u00ED jej\u00ED patogeneze, kter\u00E9 by se zjednodu\u0161en\u011B daly shrnout do 3 skupin: signalizuje p\u0159es B-bun\u011B\u010Dn\u00FD receptor (BCR), naru\u0161en\u00ED apoptick\u00FDch drah a \u00FAloha mikroprost\u0159ed\u00ED. Biologie CLL je d\u00E1le komplikov\u00E1na \u010D\u00E1ste\u010Dn\u011B rozd\u00EDlnou genez\u00ED subtyp\u016F CLL s mutovan\u00FDm a nemutovan\u00FDm IgVh. R\u00E1di bychom zde stru\u010Dn\u011B shrnuli z\u00E1kladn\u00ED molekul\u00E1rn\u011B biologick\u00E9 dr\u00E1hy diskutovan\u00E9 v patogenezi CLL a jejich souvislosti s variabiln\u00ED progn\u00F3zou onemocn\u011Bn\u00ED a nov\u011B vyv\u00EDjen\u00FDmi l\u00E9\u010Divy." .